Coya Therapeutics, Inc. (COYA) Financial Statements (2026 and earlier)

Company Profile

Business Address 12645 MEMORIAL DR., SUITE F1 #305
HOUSTON, TX 77024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments46,82338,34032,6275,934
Cash and cash equivalent46,82338,34032,6275,934
Receivables  731  
Prepaid expense8011,2339451,075
Other undisclosed current assets2,3154,0057,625176
Total current assets:49,93944,30841,1967,185
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization11396693
Other undisclosed noncurrent assets    1,117
Total noncurrent assets:1139661,211
TOTAL ASSETS:49,95044,34741,2628,396
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,6742,9764,1293,824
Accounts payable1,0611,5881,1561,815
Accrued liabilities3,6131,3882,9732,008
Deferred revenue1,198848923 
Total current liabilities:5,8723,8245,0523,824
Noncurrent Liabilities
Long-term debt and lease obligation    12,965
Long-term debt, excluding current maturities    12,965
Other undisclosed noncurrent liabilities1,050945575 
Total noncurrent liabilities:1,05094557512,965
Total liabilities:6,9224,7705,62716,789
Equity
Equity, attributable to parent43,02839,57735,636(8,394)
Preferred stock    8,794
Common stock2210
Additional paid in capital104,98980,31361,502681
Accumulated deficit(61,963)(40,737)(25,856)(17,869)
Stockholders' equity note, subscriptions receivable   (11) 
Total equity:43,02839,57735,636(8,394)
TOTAL LIABILITIES AND EQUITY:49,95044,34741,2628,396

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Revenues7,9463,5546,002 
Gross profit:7,9463,5546,002 
Operating expenses(30,501)(20,804)(13,906)(9,812)
Operating loss:(22,555)(17,250)(7,903)(9,812)
Nonoperating income
(Other Nonoperating income)		1,3321,64963964
Loss from continuing operations before income taxes:(21,223)(15,601)(7,264)(9,748)
Income tax expense (benefit) (3)720(724) 
Other undisclosed loss from continuing operations    
Loss from continuing operations:(21,226)(14,881)(7,988)(9,748)
Other undisclosed net loss    (2,497)
Net loss available to common stockholders, diluted:(21,226)(14,881)(7,988)(12,245)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Net loss:(21,226)(14,881)(7,988)(12,245)
Comprehensive loss, net of tax, attributable to parent:(21,226)(14,881)(7,988)(12,245)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: